Refine by
Biologic Therapeutic Articles & Analysis
10 articles found
Recombinant protein expression is a cornerstone of modern biopharmaceutical development, providing the means to produce proteins with therapeutic potential, enzymes, and antibodies. Among various expression systems, Chinese Hamster Ovary (CHO) cells have emerged as the preferred choice for many researchers and pharmaceutical companies. This article delves into the significance of recombinant ...
Introduction Good Manufacturing Practice (GMP) cell banks play a crucial role in the biopharmaceutical industry, serving as foundational repositories of cell lines used for the production of therapeutic biological products. Characterization of these cell banks is essential to ensure the safety, efficacy, and consistency of the biopharmaceuticals derived from them. This article will explore the ...
Knockin cell line generation represents a pivotal advancement in genetic engineering, providing vital tools for biological research and therapeutic development. This process involves the integration of specific DNA sequences into precise loci within the genome, allowing scientists to explore gene function, model diseases, and develop new treatments. Understanding Knockin Cell Line Generation At ...
Peptidomimetics are structural analogs of peptides or proteins that mimic their biological activities. They are designed to overcome limitations associated with peptides, such as poor stability and bioavailability by preserving or enhancing their functions. Peptidomimetic development involves the design and synthesis of molecules that mimic three-dimensional structures and functional groups of ...
Fc fusion protein (Fc-Fusion) has a complex and diverse molecular structure, and may contain glycosylation modification sites at amino acid 297 of its Fc fragment and the Fab region of some molecules. Moreover, its biological ligands are structurally diverse, and their glycosylation modifications may also be complex, usually involving multiple N-glycan and O-glycan sites and a large number of ...
Scientists continuously face pressure to purify biologics like protein therapeutics with maximum yield while minimizing cost and developing processes as quickly as possible. Downstream processing often accounts for more than half the cost of goods overall and significantly impacts manufacturing timelines. Affinity chromatography manages to achieve high purity and yield as well as enabling ...
By applying a proprietary operating system to drug discovery, the Utah clinical-stage biotechnology company expects to turn drug discovery from sequential testing into a search problem. Unmet clinical needs often serve as the fundamental driving force behind drug discovery programs. During lead discovery, an intensive search ensues to find a drug-like small molecule or biological therapeutic, ...
Most of the drugs currently in clinical use are based on small molecules and use the "occupancy-driven" mode of action to inhibit the function of proteins and play a role in the treatment of diseases. Different from traditional small molecule inhibitors and antagonists, protein degradation technology has developed rapidly in recent years because of its ability to induce the degradation of ...
Recently, Yang Hui, a researcher at Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, developed a nanofluidic chip technology to achieve high-throughput preparation of exosome drug carriers and experimentally verify the anti-tumor effect of novel exosome drug carriers. Exosomes are nanoscale particles that can be secreted into the extracellular space or body fluids by ...
Abstract The baculovirus/insect cell system is widely used for recombinant protein production, but it is suboptimal for recombinant glycoprotein production because it does not provide sialylation, which is an essential feature of many glycoprotein biologics. This problem has been addressed by metabolic engineering, which has extended endogenous insect cell N-glycosylation pathways and enabled ...